Objectives

After participating in this educational activity, attendees should be able to:

1| Recognize current treatment of ovarian cancer
2| Identify challenges in treating platinum-resistant ovarian cancer
3| Apply the finding of MIRASOL trial to clinical practice
4| Recognize and manage side effects of mirvetuximab soravtansine-gynx (MIRV)

Faculty

Faculty Disclosure

The design and content of Baystate Continuing Interprofessional Education (CE) activities support quality improvement in healthcare and provide fair and balanced views of therapeutic options. Any relevant financial relationships are mitigated prior to the educational activity.

None of the planners or faculty for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Accreditation Statement
In support of improving patient care, Baystate Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Pharmacists
Baystate Health designates this activity for a maximum of 1.0 contact hours (s) for pharmacists. Pharmacists should claim only the credit commensurate with the extent of their participation in the activity. 

For questions, please contact Frank Szczerba via email at Frank.Szczerba@baystatehealth.org